| Description |
1 online resource |
| Note |
Includes index. |
|
Print version record. |
| Contents |
Front Cover; Nanomaterials for Drug Delivery and Therapy; Copyright Page; Contents; List of Contributors; Foreword; Preface; 1 Cell and organ drug targeting; 1.1 Introduction; 1.2 Why Targeting Cell and Organ Is Required?; 1.3 Strategies for Drug Targeting; 1.3.1 Passive Targeting; 1.3.2 Inverse Targeting; 1.3.3 Active Targeting; 1.3.3.1 First order targeting; 1.3.3.2 Second order targeting; 1.3.3.3 Third order targeting; 1.3.3.4 Ligand mediated targeting; 1.3.4 Physical Targeting; 1.3.5 Dual Targeting; 1.3.6 Double Targeting; 1.4 Carriers for Drug Targeting |
|
1.4.1 The Microparticles: Microspheres and Microcapsules1.4.1.1 Application of microparticles as a carrier for targeted drug delivery; 1.4.1.1.1 Ophthalmic drug delivery; 1.4.1.1.2 Gene delivery; 1.4.1.1.3 Drug delivery for anticancer therapy; 1.4.1.1.4 Vaginal drug delivery; 1.4.1.2 Pros and cons of microparticulate delivery system; 1.4.2 Nanocarriers; 1.4.2.1 Vital nanocarriers; 1.4.2.2 Application of nanoparticles as a carrier for targeted drug delivery; 1.4.2.2.1 Intratumoral drug delivery; 1.4.2.2.2 Intrahepatic drug delivery; 1.4.2.2.3 Intracellular drug delivery |
|
1.4.2.2.4 Targeted drug delivery to the brain1.4.2.3 Pros and cons of nanocarriers; 1.4.3 Vesicular Carriers; 1.4.3.1 Liposomes; 1.4.3.1.1 Application of liposomes; 1.4.3.2 Niosomes; 1.4.3.2.1 Application of niosomes as a carrier for targeted drug delivery; 1.4.3.3 Ufasomes; 1.4.3.3.1 Application of ufasomes as a carrier for targeted drug delivery; 1.4.3.4 Pharmacosomes; 1.4.3.4.1 Application of pharmacosome in targeted delivery; 1.4.3.5 Virosomes; 1.4.3.5.1 Application of virosomes in targeted drug delivery; 1.4.3.6 Cubosomes; 1.4.3.6.1 Application of cubosomes in targeted drug delivery |
|
1.4.3.7 Pros and cons of vesicular carriers1.4.4 Cells as the Carriers for Targeted Drug Delivery; 1.4.4.1 Neutrophils; 1.4.4.2 Lymphocytes; 1.4.4.3 Fibroblasts; 1.4.4.4 Artificial cells; 1.4.4.5 Resealed erythrocytes; 1.4.4.6 Nanoerythrosomes; 1.4.4.7 Pros and cons of cell-based carriers; 1.4.5 Miscellaneous Carrier Systems; 1.4.5.1 Quantum dot; 1.4.5.2 Prodrug(s); 1.4.5.3 Monoclonal antibodies; 1.5 Future Perspectives; References; 2 Characterization of pharmaceutical nanocarriers: in vitro and in vivo studies; 2.1 Introduction; 2.2 Characterization; 2.2.1 In Vitro Parameters |
|
2.2.1.1 Presence of nanocarriers2.2.1.2 Size; 2.2.1.2.1 Photon correlation spectroscopy; 2.2.1.2.2 Transmission electron microscopy; 2.2.1.2.3 Laser diffraction study; 2.2.1.2.4 Turbidity method; 2.2.1.2.5 Nuclear magnetic resonance; 2.2.1.2.6 Filtration; 2.2.1.2.7 Optical microscopy; 2.2.1.3 Morphology; 2.2.1.3.1 Electron microscopy; 2.2.1.3.2 Atomic force microscopy; 2.2.1.4 Zeta potential; 2.2.1.5 Surface hydrophobicity; 2.2.1.5.1 Hydrophobic interaction chromatography; 2.2.1.6 Entrapment/incorporation efficiency; 2.2.1.7 Drug content; 2.2.1.8 Solubility study |
| Subject |
Nanostructured materials -- Therapeutic use.
|
|
Drug delivery systems.
|
|
Nanomedicine.
|
|
MEDICAL -- Pharmacology.
|
|
Drug delivery systems. (OCoLC)fst00898667
|
|
Nanomedicine. (OCoLC)fst01744350
|
| Added Author |
Grumezescu, Alexandru Mihai, editor.
|
| Other Form: |
Print version: Grumezescu, Alexandru Mihai. Nanomaterials for drug delivery and therapy 9780128165058 (OCoLC)1085965515 |
| ISBN |
9780128166291 (electronic book) |
|
0128166290 (electronic book) |
|
9780128165058 (print) |
|
0128165057 |
|
